Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Crohn's Disease, specifically its moderate to severe form, which is a long-term condition causing inflammation of the digestive system. The study examines ozanimod, a medication taken by mouth in the form of capsules, to determine if it can help maintain improvement in patients who have already shown positive response to initial treatment.

The research aims to show how well ozanimod works compared to placebo in maintaining disease remission (a state where symptoms are minimal or absent) and improving the appearance of the intestinal lining when viewed through medical examination. The medication will be given as hard capsules that patients take by mouth. Some participants will receive ozanimod while others will receive placebo capsules that look identical to the real medication.

During the study, participants will be monitored for about one year to assess how well the treatment maintains control of their disease symptoms. The study will track various aspects of the disease, including stomach pain, bowel movements, and the condition of the intestinal lining. The maximum daily dose of ozanimod used in the study is 0.92 mg.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    After completing the 12-week induction study, your eligibility for the maintenance study will be evaluated based on your response to previous treatment.

    You must show a reduction in Crohn's Disease Activity Index (CDAI) of at least 100 points or have a score below 150 points.

    Alternatively, you may qualify if you have an average daily stool frequency score of 3 or less and average abdominal pain score of 1 or less, with neither symptom worse than when you started treatment.

  2. Step 2

    Treatment assignment

    You will be randomly assigned to receive either ozanimod capsules or placebo capsules (capsules without active medication).

    The capsules are to be taken by mouth.

    Neither you nor your doctor will know which treatment you are receiving.

  3. Step 3

    52-week treatment period

    You will take the assigned medication for 52 weeks.

    Regular assessments will monitor your CDAI score, abdominal pain, and stool frequency.

    An examination of your intestines (endoscopy) will be performed to assess healing.

    If you are taking corticosteroids, their use will be monitored during the last 12 weeks of the study.

  4. Step 4

    Safety monitoring

    Your health will be monitored throughout the study period.

    Female participants must use effective birth control methods throughout the study and for 90 days after the last dose.

    The study will track any worsening of symptoms, including an increase in CDAI score of 100 points or more above starting value and a score greater than 220.

  5. Step 5

    Final evaluation

    At week 52, final assessments will be conducted to evaluate the effectiveness of the treatment.

    These include measuring your CDAI score, examining your intestines, and evaluating tissue samples if taken.

    The study will assess whether you achieved remission (improvement) of your Crohn's disease symptoms.

Who can join the trial?

14 criteria

  • Must have completed the 12-week initial treatment phase (Induction Study) and all required assessments at Week 12
  • Must be able to provide written informed consent and follow all study procedures and visits
  • Must have achieved one of the following responses after 12 weeks of initial treatment:
    • A reduction in CDAI (Crohn's Disease Activity Index) score of at least 100 points
    • A CDAI score less than 150 points
    • An average daily stool frequency of 3 or fewer times per day
    • An average abdominal pain score of 1 or less (on a defined scale)
    • Women who can become pregnant must agree to use one of these effective birth control methods throughout the study and for 90 days after:
      • Combined hormonal contraception (pills, vaginal ring, or patch)
      • Progestogen-only contraception (pills, injection, or implant)
      • Intrauterine device (IUD)
      • Intrauterine hormone system (IUS)
      • Tubal ligation
      • Partner with vasectomy
      • Complete sexual abstinence
      • Both men and women can participate in the study

Who cannot join the trial?

17 criteria

  • Current treatment with medications that suppress the immune system (such as cyclosporine, tacrolimus, or similar drugs)
  • History of severe allergic reactions to any medications
  • Active or untreated tuberculosis infection
  • Presence of serious heart conditions or irregular heart rhythm
  • Severe liver disease or abnormal liver function tests
  • Current or recent cancer diagnosis within the past 5 years
  • Active serious infections requiring treatment
  • History of certain neurological conditions like multiple sclerosis
  • Pregnancy or breastfeeding
  • Uncontrolled high blood pressure
  • History of blood clotting disorders
  • Recent major surgery within the past 3 months
  • Current participation in other clinical trials
  • Severe kidney disease requiring dialysis
  • History of organ transplantation
  • Active substance abuse or addiction
  • Inability to follow study procedures or attend scheduled visits
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ozanimod is an oral medication used to treat moderate to severe Crohn's disease. It works by modulating the immune system to reduce inflammation in the digestive tract. This medication helps maintain periods of remission (when symptoms are under control) and improves the appearance of the intestinal lining when viewed through an endoscope. It belongs to a class of drugs called sphingosine 1-phosphate receptor modulators, which help control inflammation by affecting how immune cells move through the body.

What is already known about the treatment

Ozanimod - An oral medication approved for treating moderately to severely active Crohn's disease, belonging to the class of sphingosine-1-phosphate (S1P) receptor modulators. This drug works by preventing immune cells from leaving lymph nodes, thereby reducing inflammation in the digestive tract of patients with Crohn's disease. Taken as a daily oral capsule, ozanimod represents a newer treatment option in gastroenterology, with clinical trials demonstrating its effectiveness in maintaining clinical remission and improving endoscopic response in patients with Crohn's disease.

Investigated diseases

Crohn's Disease - A chronic inflammatory bowel disease that can affect any part of the digestive tract, from mouth to anus, but most commonly occurs in the small intestine and colon. The inflammation caused by Crohn's disease often spreads deep into the layers of affected bowel tissue, creating patches of inflamed tissue surrounded by healthy areas. Common symptoms include abdominal pain, diarrhea, fatigue, weight loss, and reduced appetite. The disease typically develops gradually, with symptoms worsening over time if left untreated. The condition can lead to complications such as intestinal strictures, fistulas, and nutritional deficiencies.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-510426-33-00Protocol codeRPC01-3203Estimated enrolment536 patientsSponsorCelgene International II S.a.r.l.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).